CenTrial Logo

Ulcerative Colitis Treatment Breakthrough: Lower Dosage of Tofacitinib Proven Effective


Clinical trial tests effectiveness of reducing the dosage of tofacitinib in ulcerative colitis patients

Tofacitinib is a prescription medication used to treat patients with immune-mediated conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis who did not respond well to other medications. It works by reducing inflammation in the body by inhibiting certain enzymes called Janus kinases that regulate the immune system.

In a recent clinical trial, researchers sought to determine whether a lower dosage of tofacitinib (5 mg) would work as well as the standard dose (10 mg) in maintaining remission in patients with ulcerative colitis. They also looked at the safety of switching from the standard to the lower dose. The study involved 140 participants randomly taking 5 or 10 mg of tofacitinib twice a day.

Both dosing regimens were similarly effective in preventing UC symptoms from returning in stable remission participants. However, more participants in the 10 mg group (90%) remained in remission compared to the 5 mg group (77%). Researchers observed that 23 out of 140 participants (16 %) had serious medical problems during the study.

In the group that took 5 mg of tofacitinib, 7 participants (10%) had at least one serious medical problem, but none were related to the study medication. In the group that took 10 mg of tofacitinib, 16 participants (23%) had at least one serious medical problem, and researchers believed 4 of them (6%) were related to the study medication. About 23% of participants in the 5 mg group reported worsening ulcerative colitis, while 20% in the 10 mg group reported worsening symptoms.

Are you interested in clinical trials near you?

You can receive free notification of a trial for this, or any other condition, by completing a short confidential health profile.
Find a clinical trial near me
In conclusion, this study provides valuable insights into the use of tofacitinib for maintaining remission in patients with moderate to severe ulcerative colitis. Both doses of tofacitinib were generally well-tolerated with no major safety concerns. These findings provide important information for clinicians when considering treatment options for patients with ulcerative colitis who have achieved stable remission with tofacitinib. Further research may help to identify optimal dosing strategies and longer-term outcomes for this patient population.

Share this article with a friend:

Get emailed clinical trial results in the categories of your choice:
Free subscription to clinical trial results

20,000 clinical trials are seeking participants.
Signup and be matched to trials near you
This free service will notify you of current and future clinical trial matches.

This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. CenTrial Data Ltd. does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content. Treatments and clinical trials mentioned may not be appropriate or available for all trial participants. Outcomes from treatments and clinical trials may vary from person to person. Consult with your doctor as to whether a clinical trial is a suitable option for your condition. Assistance from generative AI tools may have been used in writing this article.